莫西沙星注射液治疗社区获得性肺炎的疗效及预后分析

目的观察莫西沙星(MOX)注射液治疗社区获得性肺炎(CAP)的疗效。方法按随机数表法将120例CAP患者分为MOX组(n=60)和左氧氟沙星(LVF)组(n=60)。治疗7d后评估疗效,比较2组患者治疗前及治疗7d后血清炎症因子[白介素-6(IL-6)、降钙素原(PCT)、C反应蛋白(CRP)]水平差异,记录不良反应情况。结果 MOX组总有效率高于LVF组(P<0.05)。治疗7d后,2组血清IL-6、PCT、CRP水平均较治疗前显著降低,且MOX组低于LVF组(P<0.05)。MOX组、LVF组总不良反应发生率差异无统计学意义(P<0.05)。结论相较于LVF,MOX治疗CAP可进一步提升疗效,减轻炎症反应,且安全性良好,于患者病情转归有利。

Efficacy and Prognosis of Moxifloxacin Injection in the Treatment of Community-acquired Pneumonia

Objective To observe the efficacy of moxifloxacin(MOX) injection in the treatment of community-acquired pneumonia(CAP). Methods 120 patients with CAP were divided into MOX group(n=60) and levofloxacin(LVF) group(n=60) according to the random number table method. After 7 d of treatment, the efficacy was evaluated. The levels of serum inflammatory factors [interleukin-6(IL-6), procalcitonin(PCT), C-reactive protein(CRP)] were compared between the two groups before treatment and after 7 d of treatment, and the adverse reactions were recorded. Results The total effective rate in MOX group was higher than that in LVF group(P<0.05). After 7 d of treatment, the levels of serum IL-6, PCT and CRP in the two groups were significantly lower than those before treatment, and the levels in MOX group were lower than those in LVF group(P<0.05). There was no significant difference in the incidence rate of adverse reactions between MOX group and LVF group(P<0.05). Conclusion Compared with LVF, MOX in the treatment of CAP can further improve the efficacy and reduce the inflammatory response, and it has good safety and is beneficial to the disease outcomes of patients.